. Standardized effects (β, in s.d.) of primary (red) and secondary (blue) lipid traits estimated in GLGC on Europeans are plotted against estimates on Chinese. Error bars indicate the 95% confidence intervals. The theoretical lines of equality and Pearson correlation coefficients (r) for effects of primary and all traits are shown. 
Supplementary Figure 2. Manhattan plot of association P-values for (a) TG, (b) HDL-C, (c) LDL-C and (d)
TC. SNPs within loci (±1Mb of top SNP) passing exome-wide significance (horizontal dash line; P<2.69x10 -7 ) are labelled in yellow and the top SNP of each region are labelled separately in orange diamond. SNPs showing independent association after conditional analysis are denoted by cicles. 
Supplementary

Supplementary Figure 10. Quantile-quantile plots of association P-values for TG, HDL-C, LDL-C and TC.
Associations for all SNPs tested are represented in black. Green circles represent associations for 157 loci reported in GLGC et al. (2013) 1 while blue circles denotes the association after removal of SNPs mapping to the 157 known loci (±1Mb).
Supplementary Tables
Supplementary Table 1 . Summary of polymorphic variants in the combined dataset.
Variant type Frequency
Number of variants genotyped Data as mean ± standard deviation or median with interquartile range. *Age is defined as the age at blood lipid tested. † SBP added 10mmHg and DBP added 5mmHg if on anti-hypertensive drug. ‡ Natural-log-transformed before analysis. CAD: Coronary artery disease; T2DM: Type 2 diabetes mellitus; BMI: Body mass index; TC: Total cholesterol; HDL-C: High-density lipoprotein cholesterol; LDL-C: Low-density lipoprotein cholesterol; TG: Triglyceride; HT: Hypertension. Pre-or without treatment lipid levels are shown. Subjects with the use of lipid-lowering drug but with no record of pre-treatment lipid levels were excluded from the quantitative blood lipids study. Dyslipidaemia is defined as having one or more of the following criteria: (1) TG ≥ 1.7mmol/L; (2) HDL-C < 1.04 in males and < 1.29mmol/L in females; (3) LDL ≥ 3.4mmol/L; and (4) already on lipid-lowering drugs. Data as mean ± standard deviation or median with interquartile range. *Age is defined by the age at diagnosis for cases and the age at recruitment for controls. † SBP added 10mmHg and DBP added 5mmHg if on anti-hypertensive drug. ‡ Natural-log-transformed before analysis. CAD: Coronary artery disease; T2DM: Type 2 diabetes mellitus; BMI: Body mass index; TC: Total cholesterol; HDL-C: High-density lipoprotein cholesterol; LDL-C: Low-density lipoprotein cholesterol; TG: Triglyceride; HT: Hypertension. Pre-or without treatment lipid levels are shown. Subjects with the use of lipid-lowering drug but with no record of pre-treatment lipid levels were excluded from the quantitative blood lipids study. Dyslipidaemia is defined as having one or more of the following criteria: (1) TG ≥ 1.7mmol/L; (2) HDL-C < 1.04 in males and < 1.29mmol/L in females; (3) LDL ≥ 3.4mmol/L; and (4) already on lipid-lowering drugs. 
Supplementary
Hong Kong Cardiovascular Risk Factors Prevalence Study (CRISPS). The Hong Kong Cardiovascular Risk
Factors Prevalence Study (CRISPS) is an on-going population-based prospective study of cardiovascular risk factors in Hong Kong 2 . Details of the CRISPS cohort were previously described [3] [4] [5] [6] . In brief, CRISPS was first commenced as a population-based survey in 1995-1996 (CRISPS1). 2895 unrelated subjects of Chinese ancestry were selected randomly by their telephone numbers from the Hong Kong population, and were invited to undergo a comprehensive assessment of cardiovascular risks at the Queen Mary 
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Asian Exomechip
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